Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 37.06M | 40.40M | 34.35M | 25.88M | 18.55M |
Gross Profit | 31.92M | 1.25M | 3.29M | 3.52M | 401.23K |
EBITDA | -4.50M | -1.43M | -1.58M | -474.00K | -3.77M |
Net Income | -8.42M | -3.62M | -4.41M | -2.24M | -3.08M |
Balance Sheet | |||||
Total Assets | 114.46M | 120.68M | 128.35M | 58.38M | 39.43M |
Cash, Cash Equivalents and Short-Term Investments | 11.80M | 14.64M | 17.34M | 25.03M | 15.95M |
Total Debt | 1.70M | 2.15M | 2.48M | 181.00K | 315.85K |
Total Liabilities | 27.52M | 30.52M | 34.40M | 13.16M | 9.70M |
Stockholders Equity | 86.94M | 90.17M | 93.95M | 45.22M | 29.74M |
Cash Flow | |||||
Free Cash Flow | -7.18M | -285.00K | 685.00K | 1.23M | -2.14M |
Operating Cash Flow | -7.13M | 169.00K | 996.00K | 1.54M | -2.02M |
Investing Cash Flow | -53.00K | -3.14M | -59.74M | -9.84M | -362.04K |
Financing Cash Flow | 4.34M | -616.00K | 51.33M | 17.23M | 15.16M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | €6.48B | 19.09 | -1.30% | 2.17% | -0.15% | -41.88% | |
53 Neutral | AU$167.87M | ― | -5.63% | ― | -11.96% | 7.50% | |
― | $122.70M | ― | ― | ― | ― | ||
― | $66.76M | ― | -9.88% | ― | ― | ― | |
55 Neutral | AU$73.68M | ― | -457.46% | ― | 21.93% | 10.34% | |
52 Neutral | AU$75.55M | ― | -11.80% | ― | 14.56% | 13.36% | |
48 Neutral | AU$95.03M | ― | ― | ― | ― |
Alcidion Group Limited reported a record-breaking quarter with a positive operating cash flow of $7.4 million, marking the highest in the company’s history. The company achieved significant growth in new sales and contract expansions, notably with North Cumbria Integrated Care NHS Trust, which increased the total contract value to over $39 million. Alcidion ended the fiscal year with a cash balance of $17.7 million and no debt, demonstrating a strong financial position. The company’s continued expansion and deployment of its Miya Precision platform underscore its long-term value proposition and market momentum.
The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.
Alcidion Group Limited announced it will release its Q4 FY25 financial results and host an investor webcast on July 24, 2025. The webcast will feature discussions by the Group Managing Director and CEO, Kate Quirke, and CFO, Matthew Gepp, on the company’s operational and commercial highlights for the quarter. This announcement underscores Alcidion’s commitment to transparency with its stakeholders and its strategic focus on expanding its influence in the global healthcare market.
The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.
Alcidion Group Limited has upgraded its financial guidance for the fiscal year ending June 2025, expecting EBITDA to exceed $4.5 million, up from the previous forecast of over $3.0 million. This improvement is attributed to smaller contract upgrades, extensions, diligent cost management, and favorable foreign exchange movements. The company’s Miya platform continues to gain traction, leading to increased customer engagement and new opportunities, reinforcing Alcidion’s long-term value proposition and ability to address critical challenges in global hospital systems.
The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.
Alcidion Group Limited announced the cessation of 206,458 performance rights due to the lapse of conditional rights that were not satisfied by the specified date. This development may impact the company’s capital structure and could have implications for stakeholders as it reflects on the company’s performance metrics and strategic objectives.
The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.
Alcidion Group Limited has announced a change in its board of directors, with Victoria Weekes ceasing to be a director as of May 30, 2025. This update, in compliance with ASX Listing Rule 3.19A.3, is part of the company’s ongoing corporate governance and may impact its strategic direction as it continues to expand its healthcare technology services globally.
The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.